Bragi Lovetrue, Founder CSO & CTO, Demiurge Technologies AG, Switzerland
Mr. Bragi Lovetrue (Zhipan Ren) is a first-in-category expert in disruptive discovery in science and technology at the intersection of neuroscience, artificial intelligence and biotechnology. At New York University, Mr. Lovetrue designed a new research major with PhD research projects at the intersection of neuroscience, artificial intelligence and consciousness, supervised by two leading philosophers Ned Block and David Chalmers. At Carnegie Mellon University, Mr. Lovetrue was a member of the founding team adapting IBM Watson into a drug discovery platform for automatic insight extraction from biomedical literature. He also designed a pioneering 3D-CNN for fMRI data analysis at Carnegie Mellon University in 2011. Mr. Lovetrue co-founded Demiurge Technologies AG with Ms. Idonae Lovetrue in Switzerland in 2015 to pioneer the AI-based discovery of disease-modifying drug targets for CNS diseases and next-generation deep learning algorithms via large-scale cross-level neuroscience data analysis. Mr. Lovetrue was an invited keynote speaker of Human Brain Project, the MRC Laboratory of Molecular Biology, IEEE international conference, etc.